Investigation of treatment volume versus circulating blood volume during Rheocarna treatment.
Rheocarna
circulating blood volume
fibrinogen
low-density lipoprotein cholesterol
treatment volume
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
31
12
2023
accepted:
19
02
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
7
3
2024
Statut:
aheadofprint
Résumé
Rheocarna's therapeutic effect is associated with fibrinogen (Fib) and low-density lipoprotein cholesterol (LDL-C) adsorptive removal. This study aimed to retrospectively investigate the association between treatment volume (TV) and circulating blood volume (CBV) and the Fib removal rate (Fib-RR) and LDL-C-RR. CBV and TV/CBV, cut-off value (CO value), and area under the receiver operating characteristic (ROC) curve (AUC) were calculated. The Fib-RR and LDL-C-RR at the midterm and end of treatment were compared. The groups were further categorized into three groups with TV/CBV lower than or higher than the CO value at the midterm and end (midterm/end; Group L: lower than/lower than CO; Group L/H: lower than/higher than CO; Group H: higher than/higher than CO), and the Fib-RR and LDL-RR of each group at the midterm and end were compared. ROC analysis revealed a TV of 1.480 times the BV as CO value, which showed a maximum Youden index predicting a Fib-RR of 20% (AUC: 0.828). Among the three groups, Group L and Group L/H demonstrated significantly higher Fib-RR and LDL-C-RR at the end of the study than in the midterm, while Group H exhibited no difference. The results reveal that a treatment volume of 1.5 times the circulating blood volume is a sufficient solute removal capacity in the Rheocarna-enabled cases.
Identifiants
pubmed: 38453633
doi: 10.1111/1744-9987.14117
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 International Society for Apheresis and Japanese Society for Apheresis.
Références
Kimata N, Tsuchiya K, Akiba T, Nitta K. Differences in the characteristics of dialysis patients in Japan compared with those in other countries. Blood Purif. 2015;40(4):275-279.
Prasad N, Jha V. Hemodialysis in Asia. Kidney Dis (Basel). 2015;1(3):165-177.
Chi Y, Jaff M. Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheter Cardiovasc Interv. 2008;71(4):475-489.
Leskinen Y, Salenius JP, Lehtimäki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis. 2002;40(3):472-479.
Yang Y, Ning Y, Shang W, Luo R, Li L, Guo S, et al. Association of peripheral arterial disease with all-cause and cardiovascular mortality in hemodialysis patients: a meta-analysis. BMC Nephrol. 2016;17(1):195.
van Reijen NS, Hensing T, Santema TKB, Ubbink DT, Koelemay MJW. Outcomes of conservative treatment in patients with chronic limb threatening Ischaemia: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2021;62(2):214-224.
Makino H, Tamanaha T, Harada-Shiba M. LDL apheresis in Japan. Transfus Apher Sci. 2017;56(5):677-681.
Kojima S, Nakama T, Obunai K. Angiographic and clinical impact of novel low-density lipoprotein apheresis for no-option chronic limb-threatening ischemia. Ther Apher Dial. 2023;27(1):186-187.
Ohkubo A, Sakurasawa T, Hoshikawa Y, Usui M, Hoshi M, Shiga T, et al. Evaluation of the treatment volume and removal rate of Rheocarna: a noveladsorption-type blood purification device for patients with chronic limb-threatening ischemia. Ther Apher Dial. 2023;27(6):1017-1022.
Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51(2):224-232.
Nakamura Y, Kumada Y, Kawai N, Ishida N. Rheocarna® therapy after distal bypass surgery distal bypass surgery. SAGE Open Med. 2023;11:2050312131192813.
Jung F, Pindur G, Kiesewetter H. Plasma viscosity dependence on proteins and lipoproteins: results of the AACHEN study. Clin Hemorheol Microcirc. 1992;12:557-571.
Imai E, Kaneko S, Hoshimoto A, Hisada R, Harano M, Anno E, et al. Short term-efficacy and tolerability of Rheocarna, a novel direct hemoperfusion adsorptive column, for chronic limb-threatening ischemia in dialysis patients: a single-center case series. Ther Apher Dial. 2023;27(6):1010-1016.
Kobayashi S, Furukawa M, Ichioka S, Horiuchi K, Kitano I, Fujii M, et al. A novel low-density lipoprotein/fibrinogen apheresis method for chronic limb-threatening ischemia in patients with poor options for revascularization: a multicenter, single-arm clinical trial. Ther Apher Dial. 2023;27(2):361-369.
Kaplan AA. Therapeutic plasma exchange: a technical andoperational review. J Clin Apher. 2013;28(1):3-10.
Churchill BM, Patri P. The Nitty-Gritties of Kt/Vurea calculations in hemodialysis and peritoneal dialysis. Indian J Nephrol. 2021;31(2):97-110.
Thompson GR. LDL apheresis. Atherosclerosis. 2003;167(1):1-13.
Tamura K, Tsurumi-Ikeya Y, Wakui H, Maeda A, Ohsawa M, Azushima K, et al. Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease. Ther Apher Dial. 2013;17(2):185-192.